Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DANAHER CORPORATION

(DHR)
  Report
Delayed Nyse  -  04:03:19 2023-01-27 pm EST
265.98 USD   +0.05%
01/26Insider Sell: Danaher
MT
01/25Cowen Adjusts Price Target on Danaher to $320 From $340, Maintains Outperform Rating
MT
01/25RBC Cuts Price Target on Danaher to $289 From $293, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Danaher Expects Core Sales Growth in 2023

01/24/2023 | 06:39am EST

By Will Feuer


Danaher Corp. said it expects adjusted sales to continue to rise in 2023, and indicated that it expects core revenue growth to accelerate after the current quarter.

The medical-and-diagnostics company said it expects adjusted base business core revenue, which excludes the effects of currency fluctuations as well as sales from the company's Covid-19 products, to rise by a high-single digit percent in 2023. For the current quarter, it expects the measure to rise by a mid-single digit percentage.

The company said it only issues sales guidance on an adjusted basis because of the difficulty in estimating the impact from factors like currency translation, acquisitions and divested product lines.

The guidance comes after Danaher posted better-than-expected results for the fourth quarter, driven by revenue growth in the company's life-sciences segment.


Write to Will Feuer at Will.Feuer@wsj.com


(END) Dow Jones Newswires

01-24-23 0638ET

All news about DANAHER CORPORATION
01/26Insider Sell: Danaher
MT
01/25Cowen Adjusts Price Target on Danaher to $320 From $340, Maintains Outperform Rating
MT
01/25RBC Cuts Price Target on Danaher to $289 From $293, Maintains Outperform Rating
MT
01/24Danaher Fourth-Quarter Results Top Views; Cuts COVID-19-Related Revenue From Sales Grow..
MT
01/24Global markets live: GE, J&J, Verizon, Lockheed Martin, Halliburton...
MS
01/24Is the Fed losing its grip on investors?
MS
01/24Sector Update: Health Care Stocks Flat to Lower Pre-Bell Tuesday
MT
01/24Sector Update: Health Care
MT
01/24Barclays Adjusts Danaher Price Target to $290 From $277, Maintains Overweight Rating
MT
01/24Transcript : Danaher Corporation, Q4 2022 Earnings Call, Jan 24, 2023
CI
More news
Analyst Recommendations on DANAHER CORPORATION
More recommendations
Financials (USD)
Sales 2022 31 019 M - -
Net income 2022 6 496 M - -
Net Debt 2022 12 130 M - -
P/E ratio 2022 30,4x
Yield 2022 0,38%
Capitalization 194 B 194 B -
EV / Sales 2022 6,64x
EV / Sales 2023 6,57x
Nbr of Employees 81 000
Free-Float 74,6%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 265,98 $
Average target price 302,25 $
Spread / Average Target 13,6%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose-Carlos GutiÚrrez-Ramos Chief Science Officer & Senior Vice President
Sadik Kassim Chief Technology Officer